Pharming Group N.V.
NASDAQ:PHARBiotechnology
+$0.28 today
- Market cap
- $882.43M
- Beta
- 0.10
- P/E (TTM)
- 77.0
- EPS (TTM)
- $0.02
Volume 0.01M
Average 0.01M
PHAR Long-term Debt
Borrowings due after more than one year.
Pharming Group N.V.NASDAQ: PHAR
Long-term Debt · Q1 FY2026 · quarter ended Mar 2026
Long-term debt rises 11.4% from a year ago
Long-term debt stood at $93.39M at the end of Q1 FY2026, up 11.4% from a year earlier and up 0.7% from the prior quarter. Over 3 fiscal years it compounded at -11.0% a year.
Context
- Long-term debt amounted to 19.1% of total assets at the end of Q1 FY2026, down 1.7 pp from a year earlier.
- Long-term debt increased in 2 of the last 3 fiscal years.
What to watch
Whether long-term debt keeps rising in the next quarterly balance sheet after a +11.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 92.72M USD
- Year-over-year change
- +14.6%
- 4-year CAGR
- -12.4%
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 92.72M | +14.6% |
| FY2024 | 2024-12-31 | 80.93M | -40.8% |
| FY2023 | 2023-12-31 | 136.6M | +3.8% |
| FY2022 | 2022-12-31 | 131.62M | -16.5% |
| FY2021 | 2021-12-31 | 157.59M | — |
Long-term Debt vs competitors
How PHAR compares with its peers on the latest reported figures
- Peers report in different currencies, so long-term debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +11.4% is the 2nd highest of 4, against a peer median of -42.7%.
- Long-term debt amounts to 19.1% of total assets for PHAR, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.75B USD | +194.0% | +17.1% | 60.2% | |
| Jun 2026 | $395.4M USD | -42.7% | -16.5% | 70.9% | |
| Mar 2026 | $93.39M USD | +11.4% | -11.0% | 19.1% | |
| Mar 2026 | $61.4M USD | — | — | 8.1% | |
| Sep 2026 | $0 USD | -100.0% | -18.0% | 0.0% | |
| Sep 2026 | €0 EUR | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding PHAR) | — | -42.7% | -16.5% | 0.0% | |
Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 217.59M | 207.34M | 61.74M | 56.89M | 146.02M |
| Short-term Investments | 0 | 0 | 151.68M | 116.96M | 33.79M |
| Net Receivables | 31.28M | 25.33M | 42.62M | 51.95M | 54.69M |
| Inventory | 30.96M | 42.33M | 56.76M | 57.7M | 64.88M |
| Other Current Assets | 257.35K | 213K | 0 | 0 | 1K |
| Total Current Assets | 282.8M | 277.5M | 316.34M | 288.32M | 299.38M |
| Property, Plant & Equipment (Net) | 37.6M | 39.15M | 33.47M | 24.12M | 23.96M |
| Goodwill | 0 | 0 | 0 | 0 | 135.5M |
| Intangible Assets | 95.04M | 75.12M | 71.27M | 63.21M | 0 |
| Long-term Investments | 9.81M | 9.73M | 10.4M | 4.38M | 9.87M |
| Tax Assets | 24.05M | 22.97M | 29.76M | 31.63M | 31.01M |
| Other Non-current Assets | 1.14M | 1.33M | 1.62M | 2.52M | 93.98K |
| Total Non-current Assets | 167.64M | 148.3M | 146.51M | 125.86M | 200.43M |
| Total Assets | 450.44M | 425.8M | 462.85M | 414.18M | 499.81M |
| Account Payables | 8.62M | 8.75M | 16.02M | 10.46M | 105.87M |
| Short-term Debt | 2.13M | 1.77M | 1.82M | 4.4M | 5.34M |
| Tax Payables | 1.71M | 2.1M | 6.23M | 3.4M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 3.4M | 1.22M |
| Total Current Liabilities | 53.02M | 59.7M | 77.97M | 76.42M | 115.79M |
| Long-term Debt | 157.59M | 131.62M | 136.6M | 80.93M | 92.72M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 187.06K | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 178.7M | 161.46M | 166.11M | 108.85M | 107.07M |
| Total Liabilities | 231.73M | 221.16M | 244.07M | 185.27M | 222.79M |
| Common Stock | 8.42M | 7.51M | 7.67M | 8.04M | 8.01M |
| Retained Earnings | (309.69M) | (256.43M) | (265.26M) | (285.27M) | (272.9M) |
| Accumulated OCI | 3.85M | (8.74M) | (2.06M) | (216.42K) | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 28.81M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 218.71M | 204.64M | 218.78M | 228.91M | 277.02M |
| Total Debt | 183.39M | 166.69M | 171.55M | 116.3M | 115.78M |
| Net Debt | (34.2M) | (40.65M) | 109.8M | 59.41M | (30.25M) |
Pharming Group N.V.
NASDAQ:PHAR
Intrinsic Alpha fair value
Locked
Current Price
$12.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.